Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.

Author
:
RJ Hartmaier
SE Trabucco
N Priedigkeit
JH Chung
CA Parachoniak
Vanden Borre
S Morley
M Rosenzweig
LM Gay
ME Goldberg
J Suh
S Ali
J Ross
B Leyland-Jones
B Young
C Williams
B Park
M Tsai
B Haley
J Peguero
RD Callahan
I Sachelarie
J Cho
JM Atkinson
A Bahreini
AM Nagle
SL Puhalla
RJ Watters
Z Erdogan-Yildirim
L Cao
S Oesterreich
A Mathew
PC Lucas
NE Davidson
AM Brufsky
GM Frampton
PJ Stephens
J Chmielecki
AV Lee
Abstract
:

ER-positive metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated endocrine-therapy resistance, recurrent ESR1 fusion proteins have yet to be identified in advanced breast cancer.
Year of Publication
:
2018
Journal
:
Annals of oncology : official journal of the European Society for Medical Oncology
Date Published
:
2018
ISSN Number
:
0923-7534
URL
:
https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdy025
DOI
:
10.1093/annonc/mdy025
Short Title
:
Ann Oncol
Download citation